Coronavirus Clinical Trial
Official title:
A Phase 2/3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19
Verified date | July 2023 |
Source | University of Oxford |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in healthy UK volunteers.
Status | Active, not recruiting |
Enrollment | 12390 |
Est. completion date | March 31, 2024 |
Est. primary completion date | March 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adults aged 18 - 55 years (groups 4, 5, 6 and 11) - Adults aged 56-69 years (groups 1, 7, and 9) - Adults aged 70 years and older (groups 2, 8, and 10) - Able and willing (in the Investigator's opinion) to comply with all study requirements. - Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner and access all medical records when relevant to study procedures. - For females of childbearing potential only, willingness to practice continuous effective contraception (see below) during the study and a negative pregnancy test on the day(s) of screening and vaccination. - Agreement to refrain from blood donation during the course of the study. - Provide written informed consent. Additional Inclusion criteria to Group 12 (HIV sub-study): - HIV positive - Receiving antiretroviral therapy - Undetectable HIV viral load - CD4>350 cells/mL Exclusion Criteria: • Participation in COVID-19 prophylactic drug trials for the duration of the study. Note: Participation in COVID-19 treatment trials is allowed in the event of hospitalisation due to COVID-19. The COV002 study team should be informed as soon as possible. • Participation in SARS-CoV-2 serological surveys where participants are informed of their serostatus for the duration of the study. Note: Disclosure of serostatus post enrolment may accidently unblind participants to group allocation. Participation in COV002 can only be allowed if volunteers are kept blinded to their serology results from local/national serological surveys - Receipt of any vaccine (licensed or investigational) other than the study intervention within 30 days before and after each study vaccination, with the exception of the licensed seasonal influenza vaccination and the licensed pneumococcal vaccination. Participants will be encouraged to receive these vaccinations at least 7 days before or after their study vaccine. - Prior or planned receipt of an investigational or licensed vaccine or product likely to impact on interpretation of the trial data (e.g. Adenovirus vectored vaccines, any coronavirus vaccines). This exclusion criteria will not apply to group 11, as recruitment will be targeted at those volunteers who previously received a ChAdOx1 vectored vaccine. - Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate. - Any confirmed or suspected immunosuppressive or immunodeficient state (except group 12, where HIV infected participants are allowed); asplenia; recurrent severe infections and use of immunosuppressant medication within the past 6 months, except topical steroids or short-term oral steroids (course lasting =14 days) - History of allergic disease or reactions likely to be exacerbated by any component of ChAdOx1 nCoV-19 or MenACWY - Any history of angioedema. - Any history of anaphylaxis. - Pregnancy, lactation or willingness/intention to become pregnant during the study. - Current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ). - History of serious psychiatric condition likely to affect participation in the study. - Bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture. - Continuous use of anticoagulants, such as coumarins and related anticoagulants (i.e. warfarin) or novel oral anticoagulants (i.e. apixaban, rivaroxaban, dabigatran and edoxaban) - Suspected or known current alcohol or drug dependency. - Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data. - Severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder and neurological illness (mild/moderate well controlled comorbidities are allowed) - History of laboratory confirmed COVID-19 (except groups 5d, 5e, 5f, 9, 10 and 11). - Seropositivity to SARS-CoV-2 before enrolment (except groups 5d, 5e, 5f, 9, 10 and 11) - NB: volunteers with previous NAAT positive results are also allowed in groups 9, 10 and 11 Additional Exclusion criteria to Groups 4, 6, 9 and 10 - History of allergic disease or reactions likely to be exacerbated by Paracetamol - Note: Caution should be taken when recommending paracetamol to adults who already take paracetamol chronically Re-vaccination exclusion criteria (two-dose groups only) - Anaphylactic reaction following administration of vaccine - Pregnancy. An exception to this will be prior to receipt of a booster dose at extra visit B. If a pregnant woman has discussed vaccination with their usual clinician (e.g. GP) and chooses to receive a COVID-19 vaccination, this may be administered by the trial team as part of extra visit B. (Protocol 19.0) or as part of the provision of treatment to controls. - Any AE that in the opinion of the Investigator may affect the safety of the participant or the interpretation of the study results |
Country | Name | City | State |
---|---|---|---|
United Kingdom | University Hospitals Birmingham NHS Foundation Trust | Birmingham | |
United Kingdom | North Bristol NHS Trust | Bristol | |
United Kingdom | University Hospitals Bristol and Weston NHS Foundation Trust | Bristol | |
United Kingdom | NIHR Cambridge Clinical Research Facility | Cambridge | |
United Kingdom | Castle Hill Hospital | Cottingham | Hull |
United Kingdom | NHS Lothian, Western General Hospital | Edinburgh | |
United Kingdom | Glasgow University and NHS Greater Glasgow & Clyde, New Lister Building, Glasgow Royal Infirmary & Queen Elizabeth University Hospital | Glasgow | |
United Kingdom | Liverpool School of Tropical Medicine (LSTM), Accelerator Research Clinic. Clinical Sciences Accelerator | LIverpool | |
United Kingdom | Guy's and St Thomas' NHS Foundation Trust, Department of Infection, St Thomas Hospital | London | |
United Kingdom | Imperial College Healthcare NHS Trust | London | |
United Kingdom | London North West University Healthcare Trust (LNWUH), Northwick Park Hospital | London | |
United Kingdom | St Georges University Hospital NHS Foundation Trust | London | Tooting |
United Kingdom | University College London Hospitals NHS Foundation Trust | London | |
United Kingdom | The Newcastle upon Tyne Hospitals NHS Foundation Trust, Royal Victoria Infirmary | Newcastle upon Tyne | |
United Kingdom | Public Health Wales | Newport | |
United Kingdom | University of Nottingham Health Service, Cripps Health Centre, University Park | Nottingham | |
United Kingdom | CCVTM, University of Oxford, Churchill Hospital | Oxford | |
United Kingdom | John Radcliffe Hospital | Oxford | |
United Kingdom | Sheffield Teaching Hospitals, Royal Hallamshire Hospital | Sheffield | |
United Kingdom | University Hospital Southampton NHS Foundation Trust | Southampton | Hampshire |
Lead Sponsor | Collaborator |
---|---|
University of Oxford |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Exploratory Immunology by virus neutralising antibody assays | Virus neutralising antibody (NAb) assays against live and/or pseudotype SARS-CoV-2 virus | 6 months | |
Other | Exploratory Immunology by flow cytometry | Cell analysis by flow cytometry assays | 6 months | |
Other | Exploratory Immunology by functional antibody assays | Functional antibody assays | 6 months | |
Other | Exploratory Immunology: anti-vector immunity | Anti-vector immunity induced by 1 or 2 doses of ChAdOx1 nCoV-19 | 6 months | |
Other | Measure exposure to COVID-19 | Reported by weekly survey to collect information about cases amongst household contacts and friends, contact with the general public, infection control procedures | 6 months | |
Other | Exploratory efficacy against infection: assess efficacy of the candidate ChAdOx1 nCoV-19 against SARS-CoV-2 infection by PCR or NAAT | Number of PCR or NAAT positive cases of COVID-19 infection | 6 months | |
Other | Exploratory efficacy against infection: assess efficacy of the candidate ChAdOx1 nCoV-19 against SARS-CoV-2 infection | Measure of differences in viral loads between those with severe, mild, and asymptomatic PCR+ SARS-CoV-2 infections | 6 months | |
Other | Compare safety, reactogenicity and immunogenicity between different manufacturing batches of ChAdOx1 nCoV-19 used in COV001 and COV002 | Differences in safety, reactogenicity and immunogenicity profiles between Group 1 in COV001 and Group 5 in COV002 (proportion of Grade 3 solicited AEs, occurrence of fevers, seroconversion rates at D28, neutralising antibody titres and differences in T-cell responses at D14). | 6 months | |
Other | Compare safety, reactogenicity and immunogenicity between different methods for measuring doses | Differences in safety, reactogenicity and immunogenicity profiles between Groups 1, 2, and 5A compared with Groups, 7, 8, and 5B, C and D respectively (proportion of Grade 3 solicited AEs, occurrence of fevers, seroconversion rates at D28, neutralising antibody titres and differences in T-cell responses at D14). | 6 months | |
Other | Assess vaccine induced mucosal immunity: Nasal mucosa IgA levels at D0 and D28 in a subset of individuals | Nasal mucosa IgA levels at D0 and D28 in a subset of individuals | 6 months | |
Other | Compare viral shedding on stool samples of SARS-CoV-2 PCR or NAAT positive individuals | Differences in viral shedding on stool at 7 days and beyond post SARS-CoV-2 PCR or NAAT positivity | 6 months | |
Other | Compare immunogenicity of ChAdOx1 nCoV-19 in participants receiving 1 or 2 doses in groups 1, 2, 7 and 8: differences in antibody titres | Differences in antibody titres (ELISA and Neutralising antibodies) in participants who received 1 or 2 doses of ChAdOx1 nCoV-19 (groups 1, 2, 7 and 8) | 6 months | |
Other | Compare immunogenicity of ChAdOx1 nCoV-19 in participants receiving 1 or 2 doses in groups 1, 2, 7 and 8: longevity of immune responses | Longevity of immune responses in participants who received 1 or 2 doses of ChAdOx1 nCoV-19 | 6 months | |
Other | Describe the impact of previous vaccination with other ChAdOx1 vectored vaccines on safety and immune responses to ChAdOx1 nCoV-19 | Differences reactogenicity profile, antibody titres and T-cell responses between groups 5d and 11 and their relationship with anti-vector neutralising antibody titres. | 6 months | |
Other | Assess the cell-mediated and humoral immunogenicity profile of ChAdOx1 nCoV-19 vaccine in HIV infected adults | Cell-mediated and humoral responses against SARS-Cov-2 These will be measured by the following:
Proportion of seroconversion to antibodies (Ab) against SARS-CoV-2 spike protein measured by ELISA. Interferon-gamma enzyme linked immunospot (ELISpot) responses to SARS-CoV-2 spike protein Intracellular Cytokine analyses of CD4 and CD8-specific SARS-CoV-2 spike protein responses Further exploratory immunology including immune responses to a further dose administered via the NHS national roll out |
6 months | |
Other | Assess whether increasing age and or CD4 nadir are associated with a lack of immune response in HIV infected adults: CD4 count-vaccine immune responses | Relationship between nadir CD4 count vs vaccine immune responses | 6 months | |
Other | Assess whether increasing age and or CD4 nadir are associated with a lack of immune response in HIV infected adults: age vs vaccine immune responses | Relationship between age at enrolment and vaccine immune response | 6 months | |
Other | Assess whether increasing age and or CD4 nadir are associated with a lack of immune response in HIV infected adults | Immune responses to ChAdOx1 nCoV-19 (assessed as described above) | 6 months | |
Other | Assess the safety of the candidate vaccine ChAdOx1 nCoV-19 in HIV infected adults | Measured by the following:
Occurrence of serious adverse events (SAEs) throughout the study duration Occurrence of solicited local reactogenicity signs and symptoms for 7 days following vaccination Occurrence of solicited systemic signs and symptoms for 7 days following each vaccination Occurrence of unsolicited AEs for 28 days following each vaccination |
Study duration (12 months from last vaccination) | |
Other | To assess Impact of vaccination on HIV reservoirs | Change in Total HIV DNA copies per million CD4 T cells | Study duration (12 months from last vaccination) | |
Other | To assess immunological correlates of protection in relation to occurrence of COVID-19 disease in ChAdOx1 nCoV-19 recipients | Immunological endpoints (antibody & cellular responses to SARS-COV2 spike protein) and COVID-19 disease endpoints (SARS-COV2 PCR positivity plus symptoms) in ChAdOx1 nCoV-19 recipients | Throughout the study, average of 18 months] | |
Primary | Assess the efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19 in adults aged 18 years and older. | Number of virologically confirmed (PCR or NAAT positive) symptomatic cases of COVID-19 | Study duration (12 months from last vaccination) | |
Primary | Assess the safety of the candidate vaccine ChAdOx1 nCoV-19 in adults | Occurrence of serious adverse events (SAEs) throughout the study duration. | Study duration (12 months from last vaccination) | |
Secondary | Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19: occurrence of solicited local reactogenicity signs and symptoms for 7 days following | Occurrence of solicited local reactogenicity signs and symptoms for 7 days following vaccination | 7 days post vaccination | |
Secondary | Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19: occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following | Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following vaccination | 7 days post vaccination | |
Secondary | Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19: occurrence of unsolicited adverse events (AEs) for 28 days following vaccination | Occurrence of unsolicited adverse events (AEs) for 28 days following vaccination | 28 days post vaccination | |
Secondary | Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19 through standard blood tests (full blood count, liver and kidney function tests) | Frequency of participants with clinically significant changes from baseline for safety laboratory measures (haematology and biochemistry blood results; except groups 4, 6, 9 & 10) | 6 months | |
Secondary | Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19 by measuring the number of disease enhancement episodes | Occurrence of disease enhancement episodes | Study duration (12 months from last vaccination) | |
Secondary | Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19: hospital admissions | Number of hospital admissions associated with COVID-19 | Study duration (12 months from last vaccination) | |
Secondary | Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 | Number of intensive care unit (ICU) admissions associated with COVID-19 | 6 months | |
Secondary | Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19: number of deaths | Number of deaths associated with COVID-19 | 6 months | |
Secondary | Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by measuring seroconversion rates | Proportion of people who become seropositive for non-Spike SARS-CoV-2 antigens during the study | 6 months | |
Secondary | Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by measuring incidence of Covid-19 | Proportion of people diagnosed with severe Covid-19 disease (defined according to clinical severity scales) | Study duration (12 months from last vaccination) | |
Secondary | Assess humoral immunogenicity of ChAdOx1 nCoV-19: antibody quantification | Quantify antibodies against SARS-CoV-2 spike protein (seroconversion rates) | 28 days post vaccination | |
Secondary | Assess humoral immunogenicity of ChAdOx1 nCoV-19: seroconversion | Proportion of seroconversion to antibodies against SARS-CoV-2 spike protein at Day 28 post-vaccination | 28 days post vaccination | |
Secondary | Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19 through ELISpot assays (groups 1, 2, 7 and 8 only) | Interferon-gamma (IFN-?) enzyme-linked immunospot (ELISpot) responses to SARS-CoV-2 spike protein | 6 months | |
Secondary | Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1, 2, 7 and 8 only): local reactogenicity | Occurrence of solicited local reactogenicity signs and symptoms for 7 days following booster vaccination | 7 days post vaccination | |
Secondary | Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only): systemic reactogenicity | Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following booster vaccination | 7 days post vaccination | |
Secondary | Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only) | Occurrence of unsolicited adverse events (AEs) for 28 days following booster vaccination | 28 days post vaccination | |
Secondary | Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only) through standard blood tests (full blood count, liver and kidney function tests) | Frequency of participants with clinically significant changes from baseline from pre-booster for safety laboratory measures (haematology and biochemistry blood results) | 6 months | |
Secondary | Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only) via seroconversion | Antibodies against SARS-CoV-2 spike protein at Day 56 post-vaccination (seroconversion rates) | 56 days post vaccination | |
Secondary | Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only) | Proportion of seroconversion to antibodies against SARS-CoV-2 spike protein at Day 56 post-vaccination | 56 days post vaccination |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05065827 -
Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
|
||
Recruiting |
NCT05359770 -
Association of Inspiratory Muscle Training With HD-tDCS for Assistance to Patients With Long Covid-19
|
N/A | |
Completed |
NCT04515147 -
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
|
Phase 2 | |
Not yet recruiting |
NCT06025812 -
Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)
|
N/A | |
Recruiting |
NCT05289115 -
Protocol for Assistance to Patients With Long Covid-19 Undergoing Treatment With HD-tDCS
|
N/A | |
Completed |
NCT04953078 -
A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19
|
Phase 1 | |
Completed |
NCT04779138 -
Increasing Vaccine Uptake in Underresourced Public Housing Areas
|
N/A | |
Not yet recruiting |
NCT05868239 -
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
|
N/A | |
Completed |
NCT04818164 -
Prone Position Improves End-Expiratory Lung Volumes in COVID-19 Acute Respiratory Distress Syndrome
|
||
Completed |
NCT04690413 -
NOWDx Test for the Detection of Antibodies to COVID-19
|
N/A | |
Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
Completed |
NCT04572399 -
UVA Light Device to Treat COVID-19
|
N/A | |
Recruiting |
NCT04610567 -
Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04772170 -
Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies
|
||
Recruiting |
NCT04581954 -
Inflammatory Signal Inhibitors for COVID-19 (MATIS)
|
Phase 1/Phase 2 | |
Completed |
NCT04405934 -
COG-UK Project Hospital-Onset COVID-19 Infections Study
|
N/A | |
Enrolling by invitation |
NCT04484025 -
SPI-1005 Treatment in Moderate COVID-19 Patients
|
Phase 2 | |
Completed |
NCT05572840 -
Wear Your Mask, Wash Your Hands, Don't Get COVID-19
|
N/A | |
Withdrawn |
NCT04838847 -
A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
|
Phase 3 | |
Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 |